北京大学学报(医学版) ›› 2020, Vol. 52 ›› Issue (2): 227-233. doi: 10.19723/j.issn.1671-167X.2020.02.006
Wen-qing LI1,Si-mei REN2,3,△(),Xing-bo LONG3,4,Yu-qing TIAN1
摘要:
目的 筛选棕榈酰化修饰水平受雄激素诱导的蛋白,探索前列腺癌去雄激素治疗外其他潜在的治疗靶点.方法: 以LNCaP细胞为研究对象,雄激素(Methyltrienolone,R1881,5 nmol/L)或DMSO(dimethyl sulfoxide)处理LNCaP细胞24 h,同时利用人工合成的炔基棕榈酸Alk-C16 (100 μmol/L)对细胞进行代谢标记,收集细胞,裂解,提取总蛋白,加入标记有叠氮化物的琼脂糖珠 (1 mmol/L), 室温反应1 h,利用叠氮化物与Alk-C16末端炔基发生点击化学反应形成的共价键将棕榈酰化修饰蛋白富集在琼脂糖珠上,进行蛋白质谱非标记定量分析(label-free quantitation, LFQ), 比较R1881处理和非处理细胞蛋白棕榈酰化修饰变化情况,筛选棕榈酰化修饰水平受雄激素诱导的蛋白.结果: 实验共鉴定出907个潜在的棕榈酰化修饰蛋白(mascot score> 2, P<0.05), 其中有430个蛋白LFQ值至少有2次不为0.在这430个蛋白中有92个蛋白R1881处理与非处理样品LFQ比值大于 1.5(P<0.05), 说明雄激素能够显著促进该蛋白棕榈酰化修饰.利用Cytoscape软件对92个蛋白进行功能富集分类,发现已知功能蛋白可分为代谢相关,蛋白折叠相关和翻译起始相关3类,其中,代谢相关蛋白包括脂代谢(6个),糖代谢(7个)和呼吸电子传递链(8个)3部分,另外还有少量氨基酸代谢(2个)和其他代谢相关蛋白(2个).参与呼吸电子传递链的细胞色素b-c1复合体亚基2 (cytochrome b-cl complex subunit2, UQCRC2) 雄激素R1881处理和未处理样品LFQ比值最高(>3,P<0.05),说明该蛋白棕榈酰化修饰受雄激素诱导最为明显.LFQ比值最高为UQCRC2,其次为脂代谢相关的长链特异性酰基辅酶A脱氢酶(very long-chain specific acyl-CoA dehydrogenase, ACADVL)和糖代谢相关的6-磷酸葡萄糖酸脱氢酶(6-phosphogluconate dehydrogenase, PGD), 但其LFQ比值均未超过3.结论: 代谢尤其是呼吸电子传递链相关蛋白的棕榈酰化调控机制的研究可能将为前列腺癌的诊疗和靶向药的研发提供新的指导思路.
中图分类号:
[1] | Bray F, Ferlay J, Soerjomataram I , et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424. |
[2] | Chen W, Zheng R, Zhang S , et al. Cancer incidence and mortality in China, 2013[J]. Cancer Lett, 2017,401:63-71. |
[3] | Watson PA, Arora VK, Sawyers CL . Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer[J]. Nat Rev Cancer, 2015,15(12):701-711. |
[4] | Wyatt AW, Gleave ME . Targeting the adaptive molecular landscape of castration-resistant prostate cancer[J]. EMBO Mol Med, 2015,7(7):878-894. |
[5] | Bishop JL, Davies A, Ketola K , et al. Regulation of tumor cell plasticity by the androgen receptor in prostate cancer[J]. Endocr Relat Cancer, 2015,22(3):R165-182. |
[6] | Quigley DA, Dang HX, Zhao SG , et al. Genomic hallmarks and structural variation in metastatic prostate cancer[J]. Cell, 2018,175(3):889. |
[7] | Viswanathan SR, Ha G, Hoff AM , et al. Structural alterations driving castration-resistant prostate cancer revealed by linked-read genome sequencing[J]. Cell, 2018,174(2):433-447.e419. |
[8] | Aicart-Ramos C, Valero RA, Rodriguez-Crespo I . Protein palmitoylation and subcellular trafficking[J]. Biochim Biophys Acta, 2011,1808(12):2981-2994. |
[9] | Charollais J , Van Der Goot FG. Palmitoylation of membrane proteins[J]. Mol Membr Biol, 2009,26(1):55-66. |
[10] | Ko PJ, Dixon SJ . Protein palmitoylation and cancer[J]. EMBO Rep, 2018,19(10):e46666. |
[11] | Thinon E, Hang HC . Chemical reporters for exploring protein acylation[J]. Biochem Soc Trans, 2015,43(2):253-261. |
[12] | Gottlieb CD, Linder ME . Structure and function of DHHC protein S-acyltransferases[J]. Biochem Soc Trans, 2017,45(4):923-928. |
[13] | Pepinsky RB, Zeng C, Wen D , et al. Identification of a palmitic acid-modified form of human sonic hedgehog[J]. J Biol Chem, 1998,273(22):14037-14045. |
[14] | Chen S, Zhu B, Yin C , et al. Palmitoylation-dependent activation of MC1R prevents melanomagenesis[J]. Nature, 2017,549(7672):399-403. |
[15] | Yao H, Lan J, Li C , et al. Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours[J]. Nat Biomed Eng, 2019,3(4):306-317. |
[16] | Hannoush RN, Sun J . The chemical toolbox for monitoring protein fatty acylation and prenylation[J]. Nat Chem Biol, 2010,6(7):498-506. |
[17] | Hernandez JL, Davda D, Majmudar JD , et al. Correlated S-palmitoylation profiling of snail-induced epithelial to mesenchymal transition[J]. Mol Biosyst, 2016,12(6):1799-1808. |
[18] | Hannoush RN, Arenas-Ramirez N . Imaging the lipidome: omega-alkynyl fatty acids for detection and cellular visualization of lipid-modified proteins[J]. ACS Chem Biol, 2009,4(7):581-587. |
[19] | Liu NQ, Braakman RB, Stingl C , et al. Proteomics pipeline for biomarker discovery of laser capture microdissected breast cancer tissue[J]. J Mammary Gland Biol Neoplasia, 2012,17(2):155-164. |
[20] | Li W, Li W, Zou L , et al. Membrane targeting of inhibitory Smads through palmitoylation controls TGF-beta/BMP signaling[J]. Proc Natl Acad Sci USA, 2017,114(50):13206-13211. |
[21] | Liberti MV, Locasale JW . The Warburg effect: how does it benefit cancer cells[J]. Trends Biochem Sci, 2016,41(3):287. |
[22] | Li C, Zhang G, Zhao L , et al. Metabolic reprogramming in cancer cells: glycolysis, glutaminolysis, and Bcl-2 proteins as novel therapeutic targets for cancer[J]. World J Surg Oncol, 2016,14(1):15. |
[23] | Warburg O . On the origin of cancer cells[J]. Science, 1956,123(3191):309-314. |
[24] | Koppenol W, Bounds P . The Warburg effect and metabolic efficiency: recrunching the numbers[J]. Science, 2009,324:1029-1033. |
[25] | Shen LF, Chen YJ, Liu KM , et al. Role of S-palmitoylation by ZDHHC13 in mitochondrial function and metabolism in liver[J]. Sci Rep, 2017,7(1):2182. |
[26] | Crofts AR, Hong S, Wilson C , et al. The mechanism of ubihydroquinone oxidation at the Qo-site of the cytochrome bc1 complex[J]. Biochim Biophys Acta, 2013,1827(11/12):1362-1377. |
[27] | 王福 . 基于细胞色素bc1复合物三维结构的新型Q0位点抑制剂的设计与合成[D]. 华中师范大学, 2012. |
[1] | 白杲琛,宋毅,金杰,虞巍,何志嵩. 多西他赛联合卡铂治疗转移性去势抵抗性前列腺癌的临床疗效[J]. 北京大学学报(医学版), 2021, 53(4): 686-691. |
[2] | 徐涛,韩敬丽,姚伟娟. 雄激素剥夺治疗相关心血管疾病的机制与临床对策[J]. 北京大学学报(医学版), 2020, 52(4): 607-609. |
[3] | 韩硕,陈章健,周迪,郑湃,张家赫,贾光. 纳米二氧化钛经口暴露90天对大鼠粪便代谢组的影响[J]. 北京大学学报(医学版), 2020, 52(3): 457-463. |
[4] | 孙奎霞,闫存玲,李志艳,刘平,张伟,何群. 前列腺特异性抗原同源异构体2及其衍生指标在预测前列腺癌病理分级中的价值[J]. 北京大学学报(医学版), 2020, 52(2): 234-239. |
[5] | 张勇,刘畅,陈彬,陈帆,段晋瑜,张孟钧,焦剑. 糖尿病前期患者糖代谢异常与慢性牙周炎的相关性[J]. 北京大学学报(医学版), 2020, 52(1): 71-76. |
[6] | 张宽根,周雨禾,邵雅昆,梅放,由江峰,刘北英,裴斐. 肿瘤转移抑制基因LASS2/TMSG1 S248A突变体通过增加ATP6V0C表达促进前列腺癌的侵袭[J]. 北京大学学报(医学版), 2019, 51(2): 210-220. |
[7] | 肖榆冰,郭慕瑶,左晓霞. 免疫代谢与系统性红斑狼疮[J]. 北京大学学报(医学版), 2018, 50(6): 1120-1124. |
[8] | 唐旭,赵卫红,宋琴琴,殷华奇,杜依青,盛正祚,王强,张晓威,李清,刘士军,徐涛. SOX10对前列腺癌细胞增殖及侵袭的影响[J]. 北京大学学报(医学版), 2018, 50(4): 602-606. |
[9] | 邹鹏程,杨一峰,徐晓艳,刘北英,梅放,由江峰,刘启忱,裴斐 . 沉默液泡型ATP酶c亚基ATP6V0C抑制人前列腺癌细胞侵袭的分子机制[J]. 北京大学学报(医学版), 2017, 49(6): 937-947. |
[10] | 巩艳青,张崔建,何世明,李学松,周利群,郭应禄. 核转出蛋白对前列腺癌雄激素受体稳定性的调节[J]. 北京大学学报(医学版), 2017, 49(4): 569-574. |
[11] | 纪光杰,黄聪,宋刚,李学松,宋毅,周利群. 去势抵抗性前列腺癌进展时间的预测因素分析[J]. 北京大学学报(医学版), 2017, 49(4): 657-662. |
[12] | 花克涵,杨磊,张晓威,白文俊,李清,徐涛. 完全性雄激素不敏感综合征合并膀胱瘘1例报道及文献回顾[J]. 北京大学学报(医学版), 2017, 49(4): 724-729. |
[13] | 何柳,唐迅,胡永华. 绝经与心血管疾病及相关代谢紊乱的关联[J]. 北京大学学报(医学版), 2016, 48(3): 448-453. |
[14] | 杨恺惟, 虞巍, 宋毅, 黄立华, 韩文科, 何志嵩, 金杰, 周利群. 影响多西他赛联合泼尼松治疗转移性去势抵抗性前列腺癌疗效的因素分析[J]. 北京大学学报(医学版), 2015, 47(4): 592-596. |
[15] | 徐涛, 王晓峰. 前列腺癌治疗的“范式转变”——雄激素剥夺治疗应关注心血管的损害[J]. 北京大学学报(医学版), 2014, 46(4): 501-503. |
|